Articles producció científica> Medicina i Cirurgia

Characterization and risk estimate of cancer in patients with primary Sjogren syndrome

  • Identification data

    Identifier: imarina:9351752
    Authors:
    Brito-Zerón, PKostov, BFraile, GCaravia-Durán, DMaure, BRascón, FJZamora, MCasanovas, ALopez-Dupla, MRipoll, MPinilla, BFonseca, EAkasbi, Mde la Red, GDuarte-Millán, MAFanlo, PGuisado-Vasco, PPérez-Alvarez, RChamorro, AJMorcillo, CJiménez-Heredia, ISánchez-Berná, ILópez-Guillermo, ARamos-Casals, M
    Abstract:
    Background: The purpose of this study is to characterize the risk of cancer in a large cohort of patients with primary Sjogren syndrome (SjS).Methods: We had analyzed the development of cancer in 1300 consecutive patients fulfilling the 2002 SjS classification criteria. The baseline clinical and immunological characteristics and systemic activity (ESSDAI scores) were assessed at diagnosis as predictors of cancer using Cox proportional hazards regression analysis adjusted for age at diagnosis and gender. The sex-and age-specific standardized incidence ratios (SIR) of cancer were estimated from 2012 Spanish mortality data.Results: After a mean follow-up of 91 months, 127 (9.8%) patients developed 133 cancers. The most frequent type of cancer was B-cell lymphoma (including 27 MALT and 19 non-MALT B-cell lymphomas). Systemic activity at diagnosis of primary SjS correlated with the risk of hematological neoplasia and cryoglobulins with a high risk of either B-cell or non-B-cell lymphoma subtypes. Patients with cytopenias had a high risk of non-MALT B-cell and non-B-cell cancer, while those with low C3 levels had a high risk of MALT lymphomas and those with monoclonal gammopathy and low C4 levels had a high risk of non-MALT lymphomas. The estimated SIR for solid cancer was 1. 13 and 11.02 for hematological cancer. SIRs for specific cancers were 36.17 for multiple myeloma and immunoproliferative diseases, 19.41 for Hodgkin lymphoma, 6.04 for other non-Hodgkin lymphomas, 5.17 for thyroid cancer, 4.81 for cancers of the lip and oral cavity, and 2.53 for stomach cancer.Conclusions: One third of cancers developed by patients with primary SjS are B-cell lymphomas. The prognostic factors identified at SjS diagnosis differed according to the subtype of B-cell lymphoma developed. Prim
  • Others:

    Author, as appears in the article.: Brito-Zerón, P; Kostov, B; Fraile, G; Caravia-Durán, D; Maure, B; Rascón, FJ; Zamora, M; Casanovas, A; Lopez-Dupla, M; Ripoll, M; Pinilla, B; Fonseca, E; Akasbi, M; de la Red, G; Duarte-Millán, MA; Fanlo, P; Guisado-Vasco, P; Pérez-Alvarez, R; Chamorro, AJ; Morcillo, C; Jiménez-Heredia, I; Sánchez-Berná, I; López-Guillermo, A; Ramos-Casals, M
    Department: Medicina i Cirurgia
    URV's Author/s: López Dupla, Jesús Miguel
    Keywords: Sjögren syndrome Predictors Non-hodgkins-lymphoma Mortality Manifestations Malignancy Lymphoma Health-organization classification Disease-activity Cohort Cancer Autoimmune-diseases 2016 revision
    Abstract: Background: The purpose of this study is to characterize the risk of cancer in a large cohort of patients with primary Sjogren syndrome (SjS).Methods: We had analyzed the development of cancer in 1300 consecutive patients fulfilling the 2002 SjS classification criteria. The baseline clinical and immunological characteristics and systemic activity (ESSDAI scores) were assessed at diagnosis as predictors of cancer using Cox proportional hazards regression analysis adjusted for age at diagnosis and gender. The sex-and age-specific standardized incidence ratios (SIR) of cancer were estimated from 2012 Spanish mortality data.Results: After a mean follow-up of 91 months, 127 (9.8%) patients developed 133 cancers. The most frequent type of cancer was B-cell lymphoma (including 27 MALT and 19 non-MALT B-cell lymphomas). Systemic activity at diagnosis of primary SjS correlated with the risk of hematological neoplasia and cryoglobulins with a high risk of either B-cell or non-B-cell lymphoma subtypes. Patients with cytopenias had a high risk of non-MALT B-cell and non-B-cell cancer, while those with low C3 levels had a high risk of MALT lymphomas and those with monoclonal gammopathy and low C4 levels had a high risk of non-MALT lymphomas. The estimated SIR for solid cancer was 1. 13 and 11.02 for hematological cancer. SIRs for specific cancers were 36.17 for multiple myeloma and immunoproliferative diseases, 19.41 for Hodgkin lymphoma, 6.04 for other non-Hodgkin lymphomas, 5.17 for thyroid cancer, 4.81 for cancers of the lip and oral cavity, and 2.53 for stomach cancer.Conclusions: One third of cancers developed by patients with primary SjS are B-cell lymphomas. The prognostic factors identified at SjS diagnosis differed according to the subtype of B-cell lymphoma developed. Primary SjS is also associated with the development of some non-hematological cancers (thyroid, oral cavity, and stomach).
    Thematic Areas: Oncology Molecular biology Medicina ii Medicina i Hematology Farmacia Ciências biológicas iii Ciências biológicas ii Cancer research Biotecnología
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: jesusmiguel.lopez@urv.cat
    Author identifier: 0000-0002-9141-2523
    Record's date: 2024-09-07
    Papper version: info:eu-repo/semantics/publishedVersion
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Journal Of Hematology & Oncology. 10
    APA: Brito-Zerón, P; Kostov, B; Fraile, G; Caravia-Durán, D; Maure, B; Rascón, FJ; Zamora, M; Casanovas, A; Lopez-Dupla, M; Ripoll, M; Pinilla, B; Fonseca, (2017). Characterization and risk estimate of cancer in patients with primary Sjogren syndrome. Journal Of Hematology & Oncology, 10(), -. DOI: 10.1186/s13045-017-0464-5
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2017
    Publication Type: Journal Publications
  • Keywords:

    Cancer Research,Hematology,Molecular Biology,Oncology
    Sjögren syndrome
    Predictors
    Non-hodgkins-lymphoma
    Mortality
    Manifestations
    Malignancy
    Lymphoma
    Health-organization classification
    Disease-activity
    Cohort
    Cancer
    Autoimmune-diseases
    2016 revision
    Oncology
    Molecular biology
    Medicina ii
    Medicina i
    Hematology
    Farmacia
    Ciências biológicas iii
    Ciências biológicas ii
    Cancer research
    Biotecnología
  • Documents:

  • Cerca a google

    Search to google scholar